- Home
- IMUX vs QNCX Comparison
IMUX vs QNCX Comparison
Compare IMUX & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- QNCX
- Stock Information
- Founded
- IMUX 2016
- QNCX 2012
- Country
- IMUX United States
- QNCX United States
- Employees
- IMUX N/A
- QNCX N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IMUX Health Care
- QNCX Health Care
- Exchange
- IMUX Nasdaq
- QNCX Nasdaq
- Market Cap
- IMUX 102.2M
- QNCX 62.0M
- IPO Year
- IMUX N/A
- QNCX 2019
- Fundamental
- Price
- IMUX $1.12
- QNCX $1.41
- Analyst Decision
- IMUX Strong Buy
- QNCX Strong Buy
- Analyst Count
- IMUX 6
- QNCX 4
- Target Price
- IMUX $12.67
- QNCX $9.50
- AVG Volume (30 Days)
- IMUX 904.4K
- QNCX 119.3K
- Earning Date
- IMUX 05-07-2025
- QNCX 03-31-2025
- Dividend Yield
- IMUX N/A
- QNCX N/A
- EPS Growth
- IMUX N/A
- QNCX N/A
- EPS
- IMUX N/A
- QNCX N/A
- Revenue
- IMUX N/A
- QNCX N/A
- Revenue This Year
- IMUX N/A
- QNCX N/A
- Revenue Next Year
- IMUX N/A
- QNCX N/A
- P/E Ratio
- IMUX N/A
- QNCX N/A
- Revenue Growth
- IMUX N/A
- QNCX N/A
- 52 Week Low
- IMUX $0.92
- QNCX $0.51
- 52 Week High
- IMUX $2.11
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- IMUX 51.41
- QNCX 43.44
- Support Level
- IMUX $1.06
- QNCX $1.38
- Resistance Level
- IMUX $1.22
- QNCX $1.52
- Average True Range (ATR)
- IMUX 0.09
- QNCX 0.09
- MACD
- IMUX -0.01
- QNCX 0.01
- Stochastic Oscillator
- IMUX 37.50
- QNCX 40.37
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.